A total of 3 large randomized trials (ie, the PLCO Cancer Screening Trial,15 the European Randomized Study of Screening for Prostate Cancer,25 and the Göteborg trial26) sought to determine whether organized PSA screening prevents PCa-specific mortality. This evidence concerns the gene KLK3 and prostate carcinoma.